[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341521-105":59,"doc-detail-341521-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","plasma-ctdna-enhances-the-tissue-based-detection-of-oncodriver-mutations-in-colorectal-cancer","Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer","","Circulating tumor DNA (ctDNA) technology enables convenient, noninvasive monitoring of cancer genomic information. This study evaluated whether plasma ctDNA adds benefits to conventional tissue-based next-generation sequencing (NGS) for identifying targetable mutations and tumor mutational burden (TMB) in colorectal cancer (CRC). Among 76 CRC patients, ctDNA and tissue NGS were compared for concordance of actionable genes and analysis of discordance factors, alongside combined TMB assessment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasma-ctdna-enhances-the-tissue-based-detection-of-oncodriver-mutations-in-colorectal-cancer/341521/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasma-ctdna-enhances-the-tissue-based-detection-of-oncodriver-mutations-in-colorectal-cancer/341521.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of using plasma ctDNA in this CRC study?","Question",{"text":112,"@type":113},"To evaluate the supplementary benefits of plasma ctDNA alongside tissue-based NGS for identifying targetable mutations and tumor mutational burden in colorectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were plasma and tissue samples analyzed in the study?",{"text":117,"@type":113},"Both tissue and plasma samples from 76 CRC patients were collected and sequenced using NGS. The study assessed concordance in gene mutational status and examined actionable genes such as KRAS, NRAS, PIK3CA, BRAF, and ERBB2.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors were associated with discordance between ctDNA and tissue results?",{"text":121,"@type":113},"Discordance was significantly associated with gender and peritoneal metastases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341521,1790111559,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Clinical and Translational Oncology (2024) 26:1976–1987  \n[https://doi.org/10.1007/s12094-024-03422-7](https://doi.org/10.1007/s12094-024-03422-7)  \nPlasma ctDNA enhances the tissue‑based detection of oncodriver mutations in colorectal cancer  \nWei Wang1 · Yisen Huang2 · Jianqiao Kong3 · Lin Lu4 · Qianxiu Liao5 · Jingtao Zhu6 · Tinghao Wang6 · Linghua Yan7 · Min Dai8 · Zhan Chen9 · Jun You10  \nReceived: 20 November 2023 / Accepted: 24 February 2024 / Published online: 22 May 2024 © The Author(s) 2024  \nAbstract  \nPurpose The advent of circulating tumor DNA (ctDNA) technology has provided a convenient and noninvasive means to continuously monitor cancer genomic data, facilitating personalized cancer treatment. This study aimed to evaluate the supplementary benefits of plasma ctDNA alongside traditional tissue-based next-generation sequencing (NGS) in identifying targetable mutations and tumor mutational burden (TMB) in colorectal cancers (CRC) .  \nMethods Our study involved 76 CRC patients, collecting both tissue and plasma samples for NGS. We assessed the concordance of gene mutational status between ctDNA and tissue, focusing on actionable genes such as KRAS, NRAS, PIK3CA, BRAF, and ERBB2 . Logistic regression analysis was used to explore variables associated with discordance and positive mutation rates.  \nResults In total, 26 cancer-related genes were identified. The most common variants in tumor tissues and plasma samples were inAPC (57 .9% vs 19.7%), TP53 (55 .3% vs 22 .4%) and KRAS (47 .4% vs 43 .4%) . Tissue and ctDNA showed an overall concordance of 73.53% in detecting actionable gene mutations. Notably, plasma ctDNA improved detection for certain genes and gene pools. Variables significantly associated with discordance included gender and peritoneal metastases. TMB analysis revealed a higher detection rate in tissues compared to plasma, but combining both increased detection.  \nConclusions Our study highlights the importance of analyzing both tissue and plasma for detecting actionable mutations in CRC, with plasma ctDNA offering added value. Discordance is associated with gender and peritoneal metastases, and TMB analysis can benefit from a combination of tissue and plasma data. This approach provides valuable insights for personalized CRC treatment.  \nKeywords Colorectal cancer · Circulating tumor DNA · Tumor mutational burden · Concordance · Positive mutation rate  \n1 Introduction  \nColorectal cancer (CRC) stands as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths in 2020, accounting for approximately 9. 8%(over 1,880,000) of new cancer cases and 9.2%(over 915,000) of cancer fatalities in 2020 [1] . The initiation and progression of CRC are widely attributed to the presence of gene mutations in several oncogenes, prominently including KRAS, NRAS, BRAF, PIK3CA and HER2 (ERBB2), etc.[2–9] . The accurate and dynamic identification of these  \nWei Wang, Yisen Huang and Jianqiao Kong are contributed equally to this work.  \nExtended author information available on the last page of the article  \ntherapeutically targetable mutations holds significant promise for precision-based personalized treatment in CRC, ultimately enhancing patient outcomes and prognosis.  \nTumor tissue next-generation sequencing (NGS) of clinically targetable mutations is important for precise treatment for CRC, while intertumor and intratumor heterogeneity hampers the further application of tissue-based NGS [5 , 10] . In addition, tumor tissues are not always available or eligible for NGS. Recently, developed circulating tumor DNA (ctDNA) technique as a convenient and noninvasive means has been rapidly employed for dynamically obtaining and monitoring landscape of genomic information to instruct personalized cancer treatment [11, 12], which has a concordant detection efficacy with the matched tumor tissue NGS [13] but overcomes the influence of intratumor heterogeneity [14] affecting tissue NGS. ctDNA has b","cbCaieTMliK2DQCp","https://ap.wps.com/l/cbCaieTMliK2DQCp","pdf",4646780,12,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n## Keywords\n## Introduction","[{\"question\":\"What is the purpose of using plasma ctDNA in this CRC study?\",\"answer\":\"To evaluate the supplementary benefits of plasma ctDNA alongside tissue-based NGS for identifying targetable mutations and tumor mutational burden in colorectal cancer.\"},{\"question\":\"How were plasma and tissue samples analyzed in the study?\",\"answer\":\"Both tissue and plasma samples from 76 CRC patients were collected and sequenced using NGS. The study assessed concordance in gene mutational status and examined actionable genes such as KRAS, NRAS, PIK3CA, BRAF, and ERBB2.\"},{\"question\":\"What factors were associated with discordance between ctDNA and tissue results?\",\"answer\":\"Discordance was significantly associated with gender and peritoneal metastases.\"}]","Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer | PDF",1790042352,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ac2b29fd0005331450dac1e34710dda.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e00ac0dfb5f46b5a7641a7cfb20352a5.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10e42613d034873f3777f891323be0ff.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d2f4970687ab43841796ab63aa2a9a8.webp",980,1301]